Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q1 2017 call → NOWe need to determine if management conveys that outsiders are currently underweighting something the company has already done, and whether management points to a concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of reported results. Let's analyze the transcript. Management discusses strong Q1 results, growth in wholesale, retail, etc. They mention several things: SM Europe JV, China JV (not yet finalized), Schwartz & Benjamin acquisition, Madden NYC launch at Kohl's, etc. Key points: - SM Europe: "Our new joint venture, SM Europe, was the standout. Like consumers in the U.S., European consumers are responding very favorably to the Steve Madden footwear collection, and results in the JV are trending well above our initial expectations." This is already operating, and they say results are trending above expectations. But is there a recognition gap? They don't explicitly say outsiders are underweighting it. They just report strong performance. - Schwartz & Benjamin: "We are also off to a good start with our newest acquisition Schwartz & Benjamin, which made a slightly above planned sales contribution of approximately $14 million in the quarter. The integration process is moving along well and on-schedule, and while we expect the transaction to be approximately breakeven to EPS this year, we are confident that Schwartz & Benjamin can be a meaningful profit contributor in 2018 and beyond." This is already acquired, operating, but contribution is still ahead (2018). However, is there a recognition gap? They don't say outsiders are underweighting it. They just state facts. - Madden NYC: "First quarter also saw us launch a new brand which is exclusive to Kohl's called Madden NYC. The brand is available in about 450 Kohl's location and on kohls.com, and the offerings include shoes, accessories, active wear and outerwear. We're off to a very good start with strong initial sell-throughs, particularly in the footwear category. While Madden NYC made only a modest sales contribution in the quarter, the strong early performance at retail gives us confidence this can be a meaningful growth vehicle going forward." This is already launched, but contribution is modest now, and they expect meaningful growth. Again, no explicit recognition gap.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.